Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy

Published:2024-03 Issue: Volume:45 Page:100732
ISSN:2405-6308
Container-title:Clinical and Translational Radiation Oncology
language:en
Short-container-title:Clinical and Translational Radiation Oncology

Author:

Kim Kangpyo,Park Hee Chul,Yu Jeong Il,Park Joon Oh,Hong Jung Yong,Lee Kyu Taek,Lee Kwang Hyuck,Lee Jong Kyun,Park Joo Kyung,Heo Jin Seok,Shin Sang Hyun,Min Ji Hye,Kim Kyunga,Han In Woong

Funder

National Research Foundation of Korea

Ministry of Education

Publisher

Elsevier BV

Reference37 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019

2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014

3. Annual report to the nation on the status of cancer, part 1: National cancer statistics;Cronin;Cancer,2022

4. Adjuvant treatment for resectable pancreatic cancer;Chua;J Clin Oncol,2005

5. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial;Conroy;JAMA Oncol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP